Lublin

• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended recruitment
  2022-502789-26-01 4 2023-11-03 Fibrostenotic Crohn’s Disease
• A phase 1/2 study of SLN124 in patients with Polycythemia Vera Ended recruitment
  2023-503544-13-00 9 2023-11-02 Polycythemia Vera
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate … Ended recruitment
  2022-502188-39-00 4 2023-09-27 Dermatitis atopic
• A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance T … Ended recruitment
  2022-501346-30-00 5 2023-09-25 Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
• LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended recruitment
  2022-501419-15-00 5 2023-08-23 Atrial Fibrillation
• A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended recruitment
  2022-501176-26-00 5 2023-08-04 Acute Ischemic Stroke and High-Risk Transient Ischemic Attack
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended recruitment
  2022-501999-26-00 5 2023-07-12 Severe Hypertriglyceridemia (SHTG)
• A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablurs … Ended recruitment
  2024-512482-14-00 4 2023-06-21 Polycythemia Vera
• Efficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-2) Ended recruitment
  2022-500700-22-00 5 2023-05-25 Active Systemic Lupus Erythematosus (SLE)
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin … Ended recruitment
  2023-507522-16-00 5 2023-05-22 Metastatic Esophageal or Gastric Cancer
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• A research study looking at long-term treatment with Mim8 in people with haemophilia A (FRONTIER 4) Ended recruitment
  2022-502215-10-00 5 2023-05-04 Haemophilia A (with or without inhibitors)
• An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended recruitment
  2022-501480-41-00 5 2023-04-06 Psoriatic Arthritis
• Study of BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma Ended recruitment
  2022-500687-35-00 9 2023-04-04 Refractory Mantle Cell Lymphoma
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met … Ended recruitment
  2023-505816-39-00 4 2023-04-04 Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carci
• A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethas … Ended recruitment
  2023-503444-13-00 5 2023-03-29 Relapsed/refractory multiple myeloma
• A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended recruitment
  2022-500953-17-00 4 2023-03-23 Moderately to severely active ulcerative colitis

Showing 457–480 of 786 trials